Phase I clinical data for BAY86-6150, a novel recombinant factor VIIa protein (rFVIIa) being developed by Bayer HealthCare, will be presented at the XXIX International Congress of the World Federation of Hemophilia (WFH) to be held in Buenos Aires, Argentina from Saturday, July 10-Wednesday, July 14.
Data to be presented are from a phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the rFVIIa variant (BAY 86-6150) in hemophilia A or B with or without inhibitors (Abstract #07P14). This study sought to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic profiles and immunogenicity of BAY 86-6150 in non-bleeding subjects with hemophilia A or hemophilia B.
Bayer is committed to expanding scientific and clinical knowledge that improves patient care. At the Congress, Bayer will be presenting data from other globally sponsored studies and country-sponsored programs as well as hosting two satellite symposia.
UK Government donates £2 million worth of medical equipment to Ukraine